AR070869A1 - Acidos dicarboxilicos de cadena media, sus derivados para tratar desordenes metabolicos - Google Patents
Acidos dicarboxilicos de cadena media, sus derivados para tratar desordenes metabolicosInfo
- Publication number
- AR070869A1 AR070869A1 ARP090100849A AR070869A1 AR 070869 A1 AR070869 A1 AR 070869A1 AR P090100849 A ARP090100849 A AR P090100849A AR 070869 A1 AR070869 A1 AR 070869A1
- Authority
- AR
- Argentina
- Prior art keywords
- dicarboxylic acids
- medium chain
- use according
- derivatives
- chain dicarboxylic
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title 1
- 150000001991 dicarboxylic acids Chemical class 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 abstract 2
- TVIDDXQYHWJXFK-UHFFFAOYSA-N dodecanedioic acid Chemical compound OC(=O)CCCCCCCCCCC(O)=O TVIDDXQYHWJXFK-UHFFFAOYSA-N 0.000 abstract 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 235000011037 adipic acid Nutrition 0.000 abstract 1
- 239000001361 adipic acid Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000013325 dietary fiber Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 150000002314 glycerols Chemical class 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 235000013406 prebiotics Nutrition 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invencion se refiere en general a ácidos dicarboxílicos de cadena media, sus derivados y sus usos. En particular, la presente invencion se refiere a una composicion que comprende ácidos dicarboxílicos de cadena media y al uso de ácidos dicarboxílicos de cadena media y sus derivados para la preparacion de productos para tratar o prevenir desordenes metabolicos. La composicion de la presente invencion en particular bien puede ser usada para tratar o prevenir la hiperglicemia, por ejemplo diabetes. Reivindicacion 4: Uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque los ácidos dicarboxílicos de cadena media se seleccionan del grupo que consiste de ácido adípico (C6), ácido subérico (C8), ácido sebácico (C10), ácido dodecanedioico (C12) y mezcla de los mismos. Reivindicacion 5: Uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque los derivados de los ácidos dicarboxílicos de cadena media se seleccionan del grupo que consiste de formas de sal de los ácidos dicarboxílicos, preferentemente sodio, potasio, calcio, magnesio o sales de aminoácidos, y ésteres de ácidos dicarboxílicos, preferiblemente ésteres de glicerol, en particular triglicéridos, o ésteres de etanol. Reivindicacion 7: Uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque el producto comprende al menos un tipo de bacteria de grado alimenticio, en particular probioticos. Reivindicacion 9: Uso de acuerdo con una de las reivindicaciones anteriores, caracterizado porque el producto contiene al menos un prebiotico, preferiblemente seleccionado del grupo que consiste de oligosacáridos y opcionalmente contiene galactosa, manosa, soya y/o inulina; fibras dietéticas; o mezclas de las mismas. Reivindicacion 14: Uso de acuerdo con una de las reivindicaciones anteriores para tratar o prevenir trastornos relacionados con la hiperglicemia, tales como nefropatías, retinopatías, enfermedades cardiovasculares y cardiacas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20080152549 EP2100604B1 (en) | 2008-03-10 | 2008-03-10 | Medium chain dicarboxylic acids and their derivates and metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070869A1 true AR070869A1 (es) | 2010-05-12 |
Family
ID=39688777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100849 AR070869A1 (es) | 2008-03-10 | 2009-03-10 | Acidos dicarboxilicos de cadena media, sus derivados para tratar desordenes metabolicos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8962689B2 (es) |
| EP (1) | EP2100604B1 (es) |
| JP (1) | JP5462191B2 (es) |
| CN (2) | CN105456242A (es) |
| AR (1) | AR070869A1 (es) |
| AU (1) | AU2009224732B2 (es) |
| BR (1) | BRPI0909835A2 (es) |
| CA (1) | CA2718007C (es) |
| DK (1) | DK2100604T3 (es) |
| ES (1) | ES2390620T3 (es) |
| MX (1) | MX2010009883A (es) |
| PT (1) | PT2100604E (es) |
| RU (1) | RU2445955C1 (es) |
| TW (1) | TW200944196A (es) |
| WO (1) | WO2009112455A1 (es) |
| ZA (1) | ZA201007212B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2100604T3 (da) | 2008-03-10 | 2012-07-23 | Nestec Sa | Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser |
| EP2397145A1 (en) * | 2010-06-18 | 2011-12-21 | Nestec S.A. | L. johnsonii La1, B. longum NCC2705 and immune disorders |
| EP2510932A1 (en) * | 2011-04-15 | 2012-10-17 | Nestec S.A. | Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny |
| KR101101808B1 (ko) * | 2011-06-01 | 2012-01-05 | 연세대학교 산학협력단 | 아디픽산의 신규한 용도 |
| NZ711956A (en) | 2013-03-08 | 2018-06-29 | Axiom Foods Inc | Rice protein supplements |
| US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
| JP6959246B2 (ja) | 2016-03-04 | 2021-11-02 | ユニバーシティ オブ ピッツバーグ−オブ ザ コモンウェルス システム オブ ハイヤー エデュケーションＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｐｉｔｔｓｂｕｒｇｈ Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 |
| SMT202200351T1 (it) * | 2016-04-20 | 2022-09-14 | New Frontier Labs Llc | Esteri dell'acido azelaico nel trattamento della resistenza all'insulina |
| CN110868870A (zh) | 2017-05-12 | 2020-03-06 | 艾斯姆食品公司 | 大米产物及制备它们的系统和方法 |
| JP7281211B2 (ja) * | 2017-12-22 | 2023-05-25 | ジェマイル リミテッド | ジカルボン酸の新たな使用及び適用 |
| CN109200043A (zh) * | 2018-10-23 | 2019-01-15 | 华南农业大学 | 二羧酸（盐）在降低脂肪沉积和预防肥胖方面的应用 |
| US20220015404A1 (en) * | 2018-12-06 | 2022-01-20 | International Flavors & Fragrances Inc. | Traumatic acid compositions and methods for taste modulation |
| EP3891121B1 (en) * | 2018-12-06 | 2023-08-30 | International Flavors & Fragrances Inc. | Sebacic acid compositions and methods for taste modulation |
| US20210368837A1 (en) * | 2018-12-06 | 2021-12-02 | International Flavors & Fragrances Inc. | Boehmeria nivea compositions and methods for taste modulation |
| CN110205261B (zh) * | 2019-05-10 | 2020-08-04 | 湖南菲勒生物技术有限公司 | 一种母乳来源罗伊氏乳杆菌降脂及调节脂代谢节律的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2982658A (en) * | 1957-04-11 | 1961-05-02 | Wasco Chemical Co Inc | Method for coating articles of food and composition therefor |
| US3360375A (en) * | 1967-05-16 | 1967-12-26 | Paniplus Company | Yeast leavened bakery products and shortening compositions |
| JPS61130205A (ja) * | 1984-11-30 | 1986-06-18 | Sunstar Inc | アスコルビン酸を安定に配合した水系組成物 |
| JPS61171417A (ja) * | 1985-01-23 | 1986-08-02 | Wakunaga Seiyaku Kk | 抗糖尿病剤 |
| IT1232161B (it) | 1989-07-31 | 1992-01-25 | Sigma Tau Ind Farmaceuti | Uso dell'acido sebacico e di suoi derivati nell'alimentazione enterale e parentaerale e composizioni farmaceutiche contenenti tali composti |
| US5219604A (en) * | 1991-02-13 | 1993-06-15 | Nabisco, Inc. | Use of ester-bridged side chains to suppress caloric availability of fat compounds |
| EP0861598A1 (en) * | 1997-02-19 | 1998-09-02 | Rhone-Poulenc Nutrition Animale | Dicarboxylic acids as an animal feed ingredient |
| JPH10327805A (ja) | 1997-06-02 | 1998-12-15 | Yasuma Kk | マグネシウム含有食品組成物 |
| US6410305B1 (en) * | 1997-08-04 | 2002-06-25 | Biosun Systems Corporation | Treatment of animal waste |
| US6432448B1 (en) * | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| SE523771C2 (sv) * | 1999-05-21 | 2004-05-18 | Probi Ab | Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller |
| JP4580542B2 (ja) | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
| KR100654516B1 (ko) * | 2001-05-15 | 2006-12-05 | 에프. 호프만-라 로슈 아게 | 당뇨병 치료에서 ｐｐａｒ-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체 |
| MY135783A (en) | 2001-09-07 | 2008-06-30 | Meiji Dairies Corp | Nutritional composition for controlling blood sugar level |
| US20050266069A1 (en) * | 2002-09-06 | 2005-12-01 | Simmons Donald L | Stable probiotic microsphere compositions and their methods of preparation |
| FR2844453B1 (fr) | 2002-09-13 | 2006-05-19 | Agronomique Inst Nat Rech | Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii |
| AU2005278099A1 (en) * | 2004-05-28 | 2006-03-02 | Merck & Co., Inc. | Benzoureas having anti-diabetic activity |
| JP5069121B2 (ja) | 2004-11-12 | 2012-11-07 | エヌ．ブイ．・ヌートリシア | 炎症反応を急激に軽減させる食品組成物 |
| CN100364533C (zh) * | 2005-04-19 | 2008-01-30 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮滴丸及其制备方法 |
| DK2100604T3 (da) | 2008-03-10 | 2012-07-23 | Nestec Sa | Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser |
-
2008
- 2008-03-10 DK DK08152549T patent/DK2100604T3/da active
- 2008-03-10 PT PT08152549T patent/PT2100604E/pt unknown
- 2008-03-10 EP EP20080152549 patent/EP2100604B1/en not_active Not-in-force
- 2008-03-10 ES ES08152549T patent/ES2390620T3/es active Active
-
2009
- 2009-03-09 CN CN201510680983.2A patent/CN105456242A/zh active Pending
- 2009-03-09 RU RU2010141525/15A patent/RU2445955C1/ru not_active IP Right Cessation
- 2009-03-09 CA CA2718007A patent/CA2718007C/en not_active Expired - Fee Related
- 2009-03-09 CN CN2009801067665A patent/CN101959512A/zh active Pending
- 2009-03-09 BR BRPI0909835A patent/BRPI0909835A2/pt not_active IP Right Cessation
- 2009-03-09 MX MX2010009883A patent/MX2010009883A/es active IP Right Grant
- 2009-03-09 WO PCT/EP2009/052721 patent/WO2009112455A1/en not_active Ceased
- 2009-03-09 AU AU2009224732A patent/AU2009224732B2/en not_active Ceased
- 2009-03-09 JP JP2010550155A patent/JP5462191B2/ja not_active Expired - Fee Related
- 2009-03-09 US US12/921,404 patent/US8962689B2/en not_active Expired - Fee Related
- 2009-03-10 TW TW98107799A patent/TW200944196A/zh unknown
- 2009-03-10 AR ARP090100849 patent/AR070869A1/es unknown
-
2010
- 2010-10-08 ZA ZA2010/07212A patent/ZA201007212B/en unknown
-
2015
- 2015-01-09 US US14/593,609 patent/US20150125426A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201007212B (en) | 2012-03-28 |
| ES2390620T3 (es) | 2012-11-14 |
| BRPI0909835A2 (pt) | 2015-10-06 |
| US8962689B2 (en) | 2015-02-24 |
| AU2009224732B2 (en) | 2014-08-21 |
| EP2100604A1 (en) | 2009-09-16 |
| CA2718007C (en) | 2013-06-18 |
| MX2010009883A (es) | 2010-10-08 |
| WO2009112455A1 (en) | 2009-09-17 |
| TW200944196A (en) | 2009-11-01 |
| AU2009224732A1 (en) | 2009-09-17 |
| CN105456242A (zh) | 2016-04-06 |
| DK2100604T3 (da) | 2012-07-23 |
| US20150125426A1 (en) | 2015-05-07 |
| US20110002900A1 (en) | 2011-01-06 |
| CN101959512A (zh) | 2011-01-26 |
| JP2011513458A (ja) | 2011-04-28 |
| PT2100604E (pt) | 2012-07-24 |
| JP5462191B2 (ja) | 2014-04-02 |
| EP2100604B1 (en) | 2012-07-04 |
| CA2718007A1 (en) | 2009-09-17 |
| RU2445955C1 (ru) | 2012-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070869A1 (es) | Acidos dicarboxilicos de cadena media, sus derivados para tratar desordenes metabolicos | |
| CL2020000141A1 (es) | Composición solida que consisten en al menos 90% en peso de uno o mas sales de cationes derivados de lisina con aniones derivados de uno o mas ácidos grasos omega-3 poliinsaturados. (solicitud divisional 201701614). | |
| AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
| CY1110812T1 (el) | Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων | |
| BR112013018539A2 (pt) | Novas fucosil transferases e suas aplicações | |
| WO2007103160A3 (en) | Stearidonic acid for improving cardiovascular health | |
| AR056081A1 (es) | Composicion que es posible de dispersar en agua y metodo para prepararla | |
| MX338558B (es) | Producto alimenticio conteniendo formulacion de sal de mesa. | |
| BRPI0921828A2 (pt) | Bactérias que produzem ácido siálico | |
| CL2008001637A1 (es) | Composicion horneada con un sabor mejorado que comprende moleculas activas del sabor: 2,5-di-metil-4-hidroxi-3-(2h)-furanona, 5-metilfurfural, diacetilo y 2-acetil-1-pirolina; y su proceso de produccion. | |
| CO6420320A2 (es) | Productos que comprenden amidas de n-fenilpropenoil amino ácido y usos de los mismos | |
| CO2017005849A2 (es) | Proceso para aumentar la estabilidad de una composición que comprende ácidos grasos omega-6 poliinsaturados | |
| BR112012000115B8 (pt) | composição compreendendo aminoácidos e/ou peptídeos bioativos e óleo marinho em uma emulsão óleo-em-água estável, processo para a produção e seus usos | |
| NO980358L (no) | To-trinns preparat | |
| AR077745A1 (es) | Composiciones de tinte secadas por aspersion, proceso para su produccion y uso | |
| ECSP099039A (es) | Esteres de dha y su utilización en el tratamiento y la prevención de enfermedades cardiovasculares | |
| EA201001580A1 (ru) | Жевательные кондитерские изделия | |
| NO20084478L (no) | Konjugerte lipidderivater | |
| UY28209A1 (es) | Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos. | |
| AR077264A1 (es) | Metodo para producir un ester de fitoesterol y/o un ester de fitoestanol | |
| BRPI0607130A2 (pt) | copolihidroxi-alquil-glutaminas funcionalizadas por grupamentos hidrofóbicos e as respectivas aplicações, notadamente terapêuticas | |
| CA2613792A1 (en) | Methods and compositions for the prevention and treatment of inflammatory disease | |
| AR044802A1 (es) | Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos | |
| AR056170A1 (es) | Procedimiento para la preparacion de acido gamma-linolenico y/o acido estearidonico en brassicaceae y linaceae transgenicas | |
| ATE452120T1 (de) | Fettsäure-benzenediol-derivate sowie herstellungs-und verwendungsverfahren dafür |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |